Low placental growth factor levels mid-gestation predict small for gestational age in pregnant women with HIV.

IF 2.9 3区医学 Q3 IMMUNOLOGY

JAIDS Journal of Acquired Immune Deficiency Syndromes Pub Date : 2025-04-03 DOI:10.1097/QAI.0000000000003672

Caroline E Dunk, Kathleen M Powis, Justine Legbedze, Shan Sun, Keolebogile N Mmasa, Samuel W Kgole, Gosego Masasa, Sikhulile Moyo, Terence Mohammed, Lynn M Yee, Mompati O Mmalane, Joseph M Makhema, Jennifer Jao, Lena Serghides

{"title":"Low placental growth factor levels mid-gestation predict small for gestational age in pregnant women with HIV.","authors":"Caroline E Dunk, Kathleen M Powis, Justine Legbedze, Shan Sun, Keolebogile N Mmasa, Samuel W Kgole, Gosego Masasa, Sikhulile Moyo, Terence Mohammed, Lynn M Yee, Mompati O Mmalane, Joseph M Makhema, Jennifer Jao, Lena Serghides","doi":"10.1097/QAI.0000000000003672","DOIUrl":null,"url":null,"abstract":"Background: Placental growth factor (PlGF) and soluble Fms-like tyrosine kinase 1 (sFlt-1) are angiogenic factors essential for placental and fetal growth. Associations between these factors and birth outcomes among pregnant women with HIV are limited.Methods: PlGF and sFlt-1 levels were quantified by ELISA in plasma samples collected between gestational weeks 24-29 from 114 women (46 with HIV, 68 without HIV). PlGF and sFlt-1:PlGF ratios were assessed using cut-offs used for prediction of preeclampsia (PlGF <12pg/mL, PlGF <100pg/mL, sFlt-1:PlGF >85), and compared by HIV status using χ2 testing. Logistic regression models were fit to assess associations of dichotomized PlGF and sFlt1:PlGF with preterm (<37weeks) and small for gestational age (SGA) birth (<10th percentile) in all participants and stratified by HIV status.Results: Women with HIV were older than women without HIV. More women with HIV had low or very low PlGF levels (<100pg/mL: 30.4% vs 7.4%, p=0.001; <12pg/mL: 17.4% vs 1.5%, p=0.002) and sFlt-1:PlGF >85 (19.5% vs 2.9%, p=0.0036) than women without HIV. Among all pregnancies, low PlGF and high sFlt-1:PlGF ratio were significantly associated with SGA (odds ratio [95% confidence interval] for PlGF <12pg/mL: 10.3 [2.0-53], p=0.005; PlGF <100pg/mL: 5.9 [1.7-21], p=0.006; sFlt-1:PlGF >85: 10.6 [2.5-46], p=0.002), but not preterm birth. Associations remained significant after adjusting for maternal age, BMI, and elevated blood pressure. Stratification by maternal HIV status showed this association was limited to the women with HIV.Conclusion: Low PlGF levels may be a good predictive biomarker of SGA specifically for pregnant women with HIV.","PeriodicalId":14588,"journal":{"name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAIDS Journal of Acquired Immune Deficiency Syndromes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAI.0000000000003672","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Placental growth factor (PlGF) and soluble Fms-like tyrosine kinase 1 (sFlt-1) are angiogenic factors essential for placental and fetal growth. Associations between these factors and birth outcomes among pregnant women with HIV are limited.

Methods: PlGF and sFlt-1 levels were quantified by ELISA in plasma samples collected between gestational weeks 24-29 from 114 women (46 with HIV, 68 without HIV). PlGF and sFlt-1:PlGF ratios were assessed using cut-offs used for prediction of preeclampsia (PlGF <12pg/mL, PlGF <100pg/mL, sFlt-1:PlGF >85), and compared by HIV status using χ2 testing. Logistic regression models were fit to assess associations of dichotomized PlGF and sFlt1:PlGF with preterm (<37weeks) and small for gestational age (SGA) birth (<10th percentile) in all participants and stratified by HIV status.

Results: Women with HIV were older than women without HIV. More women with HIV had low or very low PlGF levels (<100pg/mL: 30.4% vs 7.4%, p=0.001; <12pg/mL: 17.4% vs 1.5%, p=0.002) and sFlt-1:PlGF >85 (19.5% vs 2.9%, p=0.0036) than women without HIV. Among all pregnancies, low PlGF and high sFlt-1:PlGF ratio were significantly associated with SGA (odds ratio [95% confidence interval] for PlGF <12pg/mL: 10.3 [2.0-53], p=0.005; PlGF <100pg/mL: 5.9 [1.7-21], p=0.006; sFlt-1:PlGF >85: 10.6 [2.5-46], p=0.002), but not preterm birth. Associations remained significant after adjusting for maternal age, BMI, and elevated blood pressure. Stratification by maternal HIV status showed this association was limited to the women with HIV.

Conclusion: Low PlGF levels may be a good predictive biomarker of SGA specifically for pregnant women with HIV.

查看原文本刊更多论文

背景：胎盘生长因子（PlGF）和可溶性Fms样酪氨酸激酶1（sFlt-1）是胎盘和胎儿生长所必需的血管生成因子。这些因子与感染艾滋病病毒的孕妇的分娩结果之间的关系十分有限：采用 ELISA 方法对 114 名孕妇（46 名感染 HIV，68 名未感染 HIV）在孕 24-29 周期间采集的血浆样本中 PlGF 和 sFlt-1 的水平进行量化。使用预测先兆子痫的临界值（PlGF 85）评估 PlGF 和 sFlt-1:PlGF 比率，并使用 χ2 检验比较 HIV 感染状况。拟合逻辑回归模型以评估二分PlGF和sFlt1:PlGF与早产的关系（结果：感染艾滋病毒的妇女比未感染艾滋病毒的妇女年龄大。与未感染艾滋病病毒的妇女相比，感染艾滋病病毒的妇女中PlGF水平低或极低的人数（85（19.5% vs 2.9%，P=0.0036））更多。在所有孕妇中，低 PlGF 和高 sFlt-1:PlGF 比率与 SGA 显著相关（PlGF 85 的几率比[95% 置信区间]：10.6 [2.5-46]，p=0.002），但与早产无关。在对产妇年龄、体重指数和血压升高进行调整后，二者之间的关系仍然很明显。根据孕产妇的艾滋病毒感染状况进行分层后发现，这种关联仅限于感染艾滋病毒的妇女：低 PlGF 水平可能是预测 SGA 的一个很好的生物标志物，尤其适用于感染 HIV 的孕妇。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JAIDS Journal of Acquired Immune Deficiency Syndromes 医学-传染病学

CiteScore

5.80

自引率

5.60%

发文量

490

审稿时长

3-6 weeks

期刊介绍： JAIDS: Journal of Acquired Immune Deficiency Syndromes seeks to end the HIV epidemic by presenting important new science across all disciplines that advance our understanding of the biology, treatment and prevention of HIV infection worldwide. JAIDS: Journal of Acquired Immune Deficiency Syndromes is the trusted, interdisciplinary resource for HIV- and AIDS-related information with a strong focus on basic and translational science, clinical science, and epidemiology and prevention. Co-edited by the foremost leaders in clinical virology, molecular biology, and epidemiology, JAIDS publishes vital information on the advances in diagnosis and treatment of HIV infections, as well as the latest research in the development of therapeutics and vaccine approaches. This ground-breaking journal brings together rigorously peer-reviewed articles, reviews of current research, results of clinical trials, and epidemiologic reports from around the world.